As the major cancer centre in the Hunter region, the Haematology Unit at Calvary Mater Newcastle provides a comprehensive range of cancer services to the Hunter New England Local Health District including for bone marrow malignancies.

Myelodysplastic Syndromes (MDS) are a group of bone marrow failure disorders. There are several types of MDS. Each type of MDS has a variable onset, prognosis, treatment options, and risk of developing leukemia.

Calvary Mater Newcastle Haematology Senior Staff Specialist, Associate Professor Anoop Enjeti, said the certification by the Myelodysplastic Syndromes Foundation, a global organisation, was a credit to the hard work of Calvary Mater Newcastle’s haematology, clinical trials and research teams.

“This accolade is given to only a select few hospitals globally who have consistently worked towards excellence in this field. It reflects over a decade of work in this area including many clinical trials, research projects and patient care initiatives,” Associate Professor Anoop said.

“Recognition as an International Centre of Excellence for this disease means that patients who come to Calvary Mater Newcastle for treatment of their MDS receive care that is comparable to the best institutions in the world.

“Our patients can be confident they have access to world-class care, trial options and ongoing research aimed at continuous improvement.”

Calvary Mater Newcastle General Manager, Roslyn Everingham, said our staff should be proud of this achievement.

“This recognition on the international stage is a testament to the hard work and dedication of our incredible staff in the Haematology Unit. Congratulations to all involved,” Ms Everingham said.